Research Breakthroughs
Prof. Yair Reisner

Professor Yair Reisner


Professor Yair Reisner, Ph.D. and ICA-financed researcher, serves as Scientific Consultant at Tissera Inc. and has served as Chairman of its Scientific Advisory Board since April, 2004.


Professor Reisner served as a member of the Scientific Advisory Board of XTL Biopharmaceuticals Ltd. As a renowned expert in transplantation technology, Professor Reisner holds the Henry Drake Chair of Immunology at the Weizmann Institute of Science.


He is a member of the Advisory Committee of the American Society of Hematology Scientific Committee on Transplantation Biology and has been a visiting professor at the Memorial Sloane Kettering Cancer Center, Harvard University, and Columbia University.


A prolific scholar, Professor Reisner's research has been published in numerous leading scientific journals and he serves as an Associate Editor of the Journal for Experimental Hematology, as a co-editor of an electronic quarterly on haploidentical bone marrow transplantation, and on the editorial board of a number of publications.


Professor Reisner, was among the founders of XTL Biopharmaceuticals Ltd. Since 1993, XTL has developed fully human monoclonal antibodies for the treatment of hepatitis B and C. Tissera is a biotechnology company dedicated to the development of novel tissue precursor regeneration technologies for treating gene deficiencies and diseases necessitating organ transplantation, while minimizing the dosage of immunosuppressive drugs. He earned his MSc at the University of California, Berkeley, and his PhD at the Weizmann Institute of Science, Rehovot, Israel.


Thanks to the implementation of his research, the ability to overcome severe side effects of a transplant from a matching donor has been enhanced In recent years, he developed experimental animal models aimed at improving the effectiveness of the restoration of stem cells in cancer patients.



Professor Yair Reisner